{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:51:24Z","timestamp":1781675484374,"version":"3.54.5"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>FIGO stage IVA cervical cancer is frequently associated with extensive pelvic organ invasion and high treatment complexity. In selected patients with severe hemorrhage, renal dysfunction, or poor baseline condition, delivery of standard therapy may be clinically challenging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation<\/jats:title>\n                    <jats:p>We report a patient with FIGO stage IVA cervical squamous cell carcinoma presenting with massive vaginal bleeding, severe anemia, and renal dysfunction caused by extensive invasion of the rectum, bladder, distal ureter, and lower vagina. Emergent hemostatic radiotherapy achieved rapid bleeding control and clinical stabilization. Subsequently, an individualized conversion-oriented multimodal strategy integrating radiotherapy, targeted therapy, immunotherapy, and later consolidation chemotherapy was adopted with surgery as the intended endpoint. During treatment, serial image-guided radiotherapy (IGRT) monitoring prompted repeat CT simulation, target volume recontouring, and adaptive replanning according to tumor regression, enabling progressive reduction of irradiated target volumes while limiting unnecessary radiation exposure to adjacent pelvic organs. Marked tumor regression was achieved, followed by definitive radical surgery and pathologic complete response without recurrence during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case suggests that, in highly selected patients with FIGO stage IVA cervical cancer, an individualized conversion-oriented multidisciplinary strategy incorporating IGRT-based monitoring and adaptive replanning may facilitate subsequent radical surgery and durable disease control. However, further clinical validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1853610","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:05Z","timestamp":1781671925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Conversion-oriented multimodal therapy enabling definitive surgery in a patient with FIGO stage IVA cervical cancer at high risk of fistula formation: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanling","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanming","family":"He","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dongguan Hospital of Traditional Chinese Medicine","place":["Dongguan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology","place":["Foshan, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003140","article-title":"Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022","volume":"137","author":"Cao","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000386","article-title":"Stage IVA cervical cancer: outcomes of disease related complications and treatment","volume":"31","author":"Khulpateea","year":"2021","journal-title":"Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02303","article-title":"Evidence-based treatment paradigms for management of invasive cervical carcinoma","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14163934","article-title":"Treatment outcomes of computer tomography-guided brachytherapy in cervical cancer in Hong Kong: a retrospective review","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the Phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002492","article-title":"Advances in immunotherapy for cervical cancer: recent developments and future directions","volume":"32","author":"Sherer","year":"2022","journal-title":"Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-PD-1\/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S282372","article-title":"Long-term results of concurrent chemoradiotherapy combined with anti-EGFR monoclonal antibody prior to surgery in locally advanced cervical cancer: a single-institute prospective study","volume":"12","author":"Qing","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.027","article-title":"A systematic review of stage IVA cervical cancer treatment: challenges in the management of an understudied group","volume":"187","author":"Hunsberger","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq723","article-title":"Epidermal growth factor receptor as a biomarker for cervical cancer","volume":"22","author":"Soonthornthum","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4518","article-title":"Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation","volume":"69","author":"Talavera","year":"2009","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101930","article-title":"Survival outcomes and safety of nimotuzumab combined with radiotherapy \u00b1 chemotherapy for locally advanced cervical cancer","volume":"35","author":"Li","year":"2025","journal-title":"Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.994726","article-title":"Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: a meta-analysis of randomized controlled trials","volume":"12","author":"Yuan","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/apm-24-26","article-title":"Hemostatic radiotherapy: a narrative review of the literature","volume":"13","author":"Verschuren","year":"2024","journal-title":"Ann Palliat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.06.007","article-title":"Palliative radiotherapy for haemostasis in Malignancy: a systematic review","volume":"35","author":"Song","year":"2023","journal-title":"Clin Oncol (R Coll Radiol (G B))"},{"key":"B18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13014-023-02391-5","article-title":"Hemostatic radiotherapy in clinically significant tumor-related bleeding: excellent palliative results in a retrospective analysis of 77 patients","volume":"18","author":"Guhlich","year":"2023","journal-title":"Radiat Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3760\/cma.j.cn112137-20201104-03011","article-title":"clinical observational study of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer","volume":"101","author":"Chen","year":"2021","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3776","article-title":"Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma","volume":"4","author":"Lheureux","year":"2018","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2022.11.012","article-title":"Impact of adapted radiotherapy schedules on bowel sparing in node-positive cervical cancer","volume":"13","author":"Garrett","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02857","article-title":"Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells","volume":"10","author":"Lai","year":"2019","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853610\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:52:17Z","timestamp":1781671937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1853610\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1853610"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1853610","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1853610"}}